Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Amicus Therapeutics, Inc. - Common Stock (NQ:FOLD)

14.28 +0.03 (+0.21%)
Official Closing Price Updated: 4:15 PM EST, Jan 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 13,311,981
Open 14.25
Bid (Size) 14.25 (700)
Ask (Size) 14.30 (2,000)
Prev. Close 14.25
Today's Range 14.24 - 14.29
52wk Range 5.510 - 14.36
Shares Outstanding 266,555,274
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
The Great Unlocking: 2026 Opens with a Historic Surge in Large-Cap M&A Activity
The first week of 2026 has signaled a tectonic shift in the global financial landscape, as a wave of multi-billion dollar acquisitions has effectively ended the deal-making drought of the previous two... 
Via MarketMinute
Topics Artificial Intelligence Economy Energy
News headline image
Halper Sadeh LLC Encourages EKSO, FOLD, CWAN, JHG Shareholders to Contact the Firm to Discuss Their Rights
Shareholders should contact the firm as there may be limited time to enforce your rights. 
From Halper Sadeh LLC
Via GlobeNewswire

Performance

YTD
+0.1%
+0.1%
1 Month
+45.0%
+45.0%
3 Month
+75.0%
+75.0%
6 Month
+136.0%
+136.0%
1 Year
+53.5%
+53.5%

More News

Read More
Amicus Stock Surges To Near 2-Year Highs On BioMarin's $4.8B Buyout Deal ↗
Via Stocktwits
News headline image
Earnings Scheduled For November 4, 2025 ↗
Via Benzinga
News headline image
BioMarin’s $4.8 Billion Amicus Acquisition: A Strategic Pivot to Rare Disease Dominance
Via MarketMinute
Topics Economy Intellectual Property
News headline image
Biopharma’s Year-End Rollercoaster: Mereo Plummets 90% as BioMarin Seals $4.8 Billion Amicus Deal
Via MarketMinute
Topics ETFs Intellectual Property
News headline image
Amicus Therapeutics Investment Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Amicus Therapeutics, Inc. - FOLD
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
The Liquidity Vacuum: Thin Holiday Trading Sparks Volatility as 2025 Draws to a Close
Via MarketMinute
Topics Artificial Intelligence ETFs Economy
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Clearwater Analytics Holdings, Inc. (NYSE - CWAN), Katapult Holdings, Inc. (Nasdaq - KPLT), Janus Henderson Group plc (NYSE - JHG), Amicus Therapeutics, Inc. (Nasdaq
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Unusual volume stocks in Tuesday's session ↗
Via Chartmill
News headline image
Halper Sadeh LLC Encourages FOLD, VYNE, HTBK, FMNB Shareholders to Contact the Firm to Discuss Their Rights
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session. ↗
Via Chartmill
News headline image
Discover the most active stocks in Friday's session. ↗
Via Chartmill
News headline image
Which stocks are moving on Friday? ↗
Via Chartmill
News headline image
Which stocks are gapping on Friday? ↗
Via Chartmill
News headline image
FOLD Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Amicus Therapeutics, Inc. is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
News headline image
Discover the top movers in Friday's pre-market session. ↗
Via Chartmill
Breakthrough Therapies Advance as Rare Disease Burden Intensifies Across Aging Populations
Via Investor Brand Network
Topics Government
News headline image
Breakthrough Therapies Advance as Rare Disease Burden Intensifies Across Aging Populations
From BioMedWire
Via GlobeNewswire
News headline image
Healthcare Investor Exits $13 Million Stake STAAR Surgical Stake as Alcon Deal Drama Looms ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
PTC Therapeutics Swings to a Profit on $211 Million in Revenue — Is This Why a Major Fund Just Invested $32 Million? ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Dyne Therapeutics Stock Down 30% in a Year — So Why Did One Investor Add Nearly 1 Million Shares? ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Amicus Therapeutics Inc (NASDAQ:FOLD) Q3 2025 Earnings: A Landmark Quarter with Strong Profitability Beat ↗
Via Chartmill
News headline image
Amicus Therapeutics Announces Third Quarter 2025 Financial Results and Corporate Updates
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2025
From Amicus Therapeutics, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Amicus Therapeutics, Inc. - Common Stock publicly traded?
Yes, Amicus Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Amicus Therapeutics, Inc. - Common Stock trade on?
Amicus Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Amicus Therapeutics, Inc. - Common Stock?
The ticker symbol for Amicus Therapeutics, Inc. - Common Stock is FOLD on the Nasdaq Stock Market
What is the current price of Amicus Therapeutics, Inc. - Common Stock?
The current price of Amicus Therapeutics, Inc. - Common Stock is 14.28
When was Amicus Therapeutics, Inc. - Common Stock last traded?
The last trade of Amicus Therapeutics, Inc. - Common Stock was at 01/06/26 04:15 PM ET
What is the market capitalization of Amicus Therapeutics, Inc. - Common Stock?
The market capitalization of Amicus Therapeutics, Inc. - Common Stock is 3.81B
How many shares of Amicus Therapeutics, Inc. - Common Stock are outstanding?
Amicus Therapeutics, Inc. - Common Stock has 4B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.